All In Biotech

Drug Trial Radar · NCT06015308

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

224

Actual

Start

Oct 6, 2023

Primary completion

Oct 1, 2025

Study completion Jan 16, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint). Study details include: The study duration will be up to 36 weeks (for participants not entering the LTS17367 \[RIVER-AD\]). The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 \[RIVER-AD\]).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Subcutaneous injection in abdomen, outer thigh, or upper arm

  • PlaceboDrug

    Subcutaneous injection in abdomen, outer thigh, or upper arm

  • Tdap vaccineBiological

    Intramuscular (IM) injection into the deltoid muscle of the upper arm

  • PPS vaccineBiological

    Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with a positive tetanus response at Week 16Time frame: Week 16

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama - Homewood- Site Number : 8401101

    Birmingham, Alabama

  • Center for Dermatology and Plastic Surgery- Site Number : 8401119

    Scottsdale, Arizona

  • Orange County Clinical Trials- Site Number : 8401271

    Anaheim, California

  • First OC Dermatology- Site Number : 8401025

    Fountain Valley, California

  • Center for Dermatology Clinical Research- Site Number : 8401018

    Fremont, California

  • Valley Research- Site Number : 8401097

    Fresno, California

  • Paradigm Clinical Research Centers- Site Number : 8401273

    La Mesa, California

  • Sunwise Clinical Research- Site Number : 8401022

    Lafayette, California

  • Antelope Valley Clinical Trials- Site Number : 8401099

    Lancaster, California

  • Torrance Clinical Research- Site Number : 8401027

    Lomita, California

  • Clinical Science Institute- Site Number : 8401028

    Santa Monica, California

  • Velocity Clinical Research - Denver Site Number : 8401168

    Denver, Colorado

  • Daxia Trials- Site Number : 8401145

    Boca Raton, Florida

  • Encore Medical Research of Boynton Beach- Site Number : 8401030

    Boynton Beach, Florida

  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111

    Fort Myers, Florida

  • Doral Medical Research- Site Number : 8401094

    Hialeah, Florida

  • C&R Research Services - Kendall- Site Number : 8401029

    Kendall, Florida

  • Acevedo Clinical Research Associates- Site Number : 8401088

    Miami, Florida

  • Future Care Solution - Miami- Site Number : 8401144

    Miami, Florida

  • Sanchez Clinical Research- Site Number : 8401095

    Miami, Florida

  • Florida International Research Center- Site Number : 8401091

    Miami, Florida

  • Wellness Clinical Research - Miami Lakes- Site Number : 8401109

    Miami Lakes, Florida

  • K2 South Orlando - South Orange Avenue- Site Number : 8401268

    Orlando, Florida

  • SEC Clinical Research- Site Number : 8401270

    Pensacola, Florida

  • Global Clinical Professionals (GCP)- Site Number : 8401045

    St. Petersburg, Florida

  • Clinical Research Trials of Florida- Site Number : 8401023

    Tampa, Florida

  • Paradigm Clinical Research - Boise- Site Number : 8401272

    Boise, Idaho

  • Skin Sciences- Site Number : 8401039

    Louisville, Kentucky

  • Velocity Clinical Research at The Dermatology Clinic- Site Number : 8401072

    Baton Rouge, Louisiana

  • BRCR Global Gretna- Site Number : 8401243

    Gretna, Louisiana

  • Boeson Research - Missoula- Site Number : 8401269

    Missoula, Montana

  • Henderson Clinical Trials- Site Number : 8401169

    Henderson, Nevada

  • Skin Search Rochester- Site Number : 8401216

    Rochester, New York

  • Velocity Clinical Research - Durham- Site Number : 8401175

    Durham, North Carolina

  • Velocity Clinical Research - Springdale- Site Number : 8401153

    Cincinnati, Ohio

  • Velocity Clinical Research - Medford- Site Number : 8401170

    Medford, Oregon

  • Vial Health - DermDox Dermatology- Site Number : 8401031

    Camp Hill, Pennsylvania

  • Velocity Clinical Research - Providence- Site Number : 8401179

    East Greenwich, Rhode Island

  • Velocity Clinical Research - Charleston - Ashley Town Center Drive- Site Number : 8401174

    Charleston, South Carolina

  • Velocity Clinical Research - Columbia- Site Number : 8401176

    Columbia, South Carolina

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.